GI Dynamics, Inc. Announces Corporate Restructuring and Departure of Chief Financial Officer
GI Dynamics Resumes Shipments of EndoBarrier® Product
GI Dynamics to Present at the 26th Annual Piper Jaffray Healthcare Conference
EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE